RAC - Charts & Price Action, page-2906

I would note - to take into account that everything changed , *RAC re-rate from late June / into July when also the COH study on bisantrene came to light .
( they had gone to such lengths to seek to disguise bisantrene as the drug - but in major publications , the actual drug names / identify must be given and used . )
This was significant work by COH .

The Sheba trial results were chosen as a paper / poster presentation at the ASH conference at the end of 2020 also.

My point is that late June & into July 2020 was a major turning point for RAC : really like a new starting point for your charts - joining fundamentals with TA .
1. The Sheba trial results (June 2020) ; &
2. the City of Hope findings that Bisantrene was No 1 out of over 250000 drug compounds for the inhibition of the FTO protein , that is significant in a broad number of cancers.
This really helps explain Bisantrenes known historical efficacy in breast, AML, renal , ovarian , lung , and other difficult cancers including melanoma, where other chemotherapy and treatments have failed & where the FTO protein is now being focused on as a potential target in these cancers .

This would all still fit with your possible theory